Cite
HARVARD Citation
Zhu, C. et al. (2022). Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. Journal of neurology, neurosurgery and psychiatry. 93 (12), pp. 1330-1337. [Online].